SCHEMBL4284674

SCHEMBL4284674

O=C(O)C1(c2ccccc2Cl)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 2/20 0.59
AKR1C1 Q04828 1/20 0.52
CRHBP P24387 1/20 0.49
CRHR2 Q13324 1/20 0.49
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 1/20 0.42
MEN1 O00255 1/20 0.41
PTGS2 P35354 1/20 0.40
FTO Q9C0B1 1/20 0.40
THRB P10828 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRL1 P41146 1/20 0.39
SLC6A4 P31645 1/20 0.39
OPRK1 P41145 1/20 0.39
GRIN1 Q05586 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30790659 1.00 HDAC4 (0.59) HDAC4AKR1C1CRHBPCRHR2KMT2A
SCHEMBL19469486 0.94 HDAC4 (0.62) HDAC4AKR1C1CRHBPCRHR2KMT2A
SCHEMBL30501932 0.94 HDAC4 (0.62) HDAC4AKR1C1CRHBPCRHR2KMT2A
SCHEMBL11097737 0.88 HDAC4 (0.51) HDAC4AKR1C1CRHBPCRHR2KMT2A
SCHEMBL21826527 0.88 HDAC4 (0.51) HDAC4AKR1C1CRHBPCRHR2KMT2A
SCHEMBL31125495 0.88 HDAC4 (0.51) HDAC4AKR1C1CRHBPCRHR2KMT2A
SCHEMBL8747357 0.84 HDAC4 (0.59) HDAC4AKR1C1CRHBPCRHR2ALDH1A1
SCHEMBL29077524 0.82 HDAC4 (0.57) HDAC4CRHBPCRHR2ALDH1A1HDAC3
SCHEMBL27035072 0.82 HDAC4 (0.49) HDAC4AKR1C1CRHBPCRHR2ALDH1A1
SCHEMBL3389625 0.80 HDAC4 (0.69) HDAC4AKR1C1CRHBPCRHR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117430609-B Purine derivative compound, preparation method and application thereof 东北农业大学 2024-05-24 CN disclosed
CN-117430609-A Purine derivative compound, preparation method and application thereof 东北农业大学 2024-01-23 CN disclosed
CN-113861072-A Preparation method of aryl cyclopropane compound 上海麦克林生化科技有限公司 2021-12-31 CN disclosed
US-20190031599-A1 INDANE DERIVATIVES AS MGLUR7 MODULATORS TAKEDA CAMBRIDGE LIMITED (GB) 2019-01-31 US disclosed
EP-3408256-A1 INDANE DERIVATIVES AS MGLUR7 MODULATORS Takeda Pharmaceutical Company Limited (JP) 2018-12-05 EP disclosed
WO-2017131221-A1 INDANE DERIVATIVES AS MGLUR7 MODULATORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-08-03 WO disclosed
WO-2014079850-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2014-05-30 WO disclosed
EP-2134692-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION Wyeth a Corporation of the State of Delaware (US) 2009-12-23 EP disclosed
WO-2009150660-A1 A PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM RELIANCE LIFE SCIENCES PVT. LTD. (IN) 2009-12-17 WO disclosed
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins WYETH (US) 2008-10-16 US disclosed
WO-2008121817-A2 QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR SELECTIN INHIBITION WYETH (US) 2008-10-09 WO disclosed
US-20060148871-A1 Metabolic stabilization of substituted adamantane ABBOTT LABORATORIES 2006-07-06 US disclosed
US-4952720-A Ortho-substituted benzyl carboxylates and fungicides which contain these compounds BASF AKTIENGSELLSCHAFT (DE) 1990-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190031599-A1 INDANE DERIVATIVES AS MGLUR7 MODULATORS GRM7, GRIN2B, GRM1 HDAC4 1499/4885AKR1C1 4515/4885CRHBP 615/4885
US-20080255192-A1 2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethoxy)quinoline-4-carboxylic acid; antiinflammtory agents; antagonists of the mammalian adhesion proteins VCAM1, ICAM1, SELE HDAC4 2710/4885AKR1C1 2640/4885CRHBP 318/4885
US-20060148871-A1 Metabolic stabilization of substituted adamantane HSD11B1, HSD17B1, HSD11B2 HDAC4 2818/4885AKR1C1 79/4885CRHBP 2306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.